Emmaus Life Sciences, Inc. Stock Other OTC
Equities
EMMA
US29137T1016
Biotechnology & Medical Research
Sales 2021 | 20.61M 28.2M | Sales 2022 | 18.39M 25.16M | Capitalization | 12.9M 17.65M |
---|---|---|---|---|---|
Net income 2021 | -15M -20.52M | Net income 2022 | -10M -13.68M | EV / Sales 2021 | 4.97 x |
Net Debt 2021 | 20.13M 27.54M | Net Debt 2022 | 28.8M 39.4M | EV / Sales 2022 | 2.27 x |
P/E ratio 2021 |
-5.16
x | P/E ratio 2022 |
-1.21
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 48.23% |
Managers | Title | Age | Since |
---|---|---|---|
George Sekulich
PSD | President | 59 | 19-04-30 |
Willis Lee
CHM | Chairman | 64 | 19-07-16 |
Yasushi Nagasaki
DFI | Director of Finance/CFO | 57 | 11-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Wei Peu Zen
BRD | Director/Board Member | 71 | 19-07-16 |
Willis Lee
CHM | Chairman | 64 | 19-07-16 |
Ian Zwicker
BRD | Director/Board Member | 77 | 19-07-16 |
1st Jan change | Capi. | |
---|---|---|
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |